You just read:

Protagonist Therapeutics Announces First Patient Dosed in a Phase 2 Study of Oral IL-23 Receptor Antagonist PTG-200 (JNJ-67864238) in the Treatment of Crohn's Disease

News provided by

Protagonist Therapeutics, Inc.

Nov 06, 2019, 16:01 ET